Base Excision Repair Factors are Promising Prognostic and Predictive Markers in Cancer

Lucy Gossage(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Christina J. Perry(Florey Institute of Neuroscience and Mental Health), Rachel Abbotts(University of Nottingham)

Current Molecular Pharmacology

December 29, 2011

10.2174/1874467211205010115

Cited by 23

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

|New England Journal of Medicine|2020|1.8k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374